-
Procter & Gamble Company v. Teva Pharmaceuticals USA Inc. DC
- 1:08-cv-00191
- D. Del.
- Judge: Joseph J. Farnan, Jr
- Filed: 04/04/2008
- Closed: 05/23/2008
- Latest Docket Entry: 06/23/2009
- PACER
- Docket updated daily
1
Plaintiff
1
Defendant
2
Accused
Products
1
Patent-in-Suit
50
Days in
Litigation
-
Procter & Gamble Company v. Teva Pharmaceuticals USA Inc. DC
- 1:08-cv-00191
- D. Del.
- Judge: Joseph J. Farnan, Jr
- Filed: 04/04/2008
- Closed: 05/23/2008
- Latest Docket Entry: 06/23/2009
- PACER
- Docket updated daily
Cause of Action
Infringement
Market Sector
Biotech and Pharma
Court
Assigned Judge
Outcome Summary
- Patent Information
-
Validity & Enforceability
| Claim # | Claim Text | Outcome |
|---|---|---|
| 4 |
A diphosphonic and acid compound, or pharmaceutically-acceptable salt or ester thereof, which is 2-(3-pyridyl)-1-hydroxyethane diphosphonic acid.
|
Enforceable and Valid
Entry 10 |
| 16 |
A pharmaceutical composition according to claim 14, wherein said diphosphonic acid compound is 2-(3-pyridyl)-hydroxyethane diphosphonic acid.
|
Enforceable and Valid
Entry 10 |
| 23 |
A method of treating diseases associated with abnormal calcium and phosphate metabolism, comprising administering to a person in need of such treatment a safe and effective amount of a composition of claim 16.
|
Enforceable and Valid
Entry 10 |
-
Infringement
Teva Pharmaceuticals USA, Inc.
- 1 Detail
| Accused Product | Patent # | Claim # | Outcome |
|---|---|---|---|
| Tablet with 35 mg risedronate sodium and 1250 mg calcium carbonate | US 5,583,122 A |
4, 16, 23
|
Infringement
Entry 10
|
